PATIENT SELF-ASSESSMENTS IN ADVANCED PARKINSON'S DISEASE WITHIN UPDRS AND "OFF" TIME SUBGROUPS: COMPARISON OF IPX066 WITH IMEDIATE-RELEASE CARBIDOPA-LEVODOPA

被引：0
|
作者：
Rubens, R. [1 ]
Rustay, N. R. [1 ]
Khanna, S. [1 ]
Kell, S. [1 ]
Gupta, S. [1 ]
机构：
[1] Impax Labs Inc, Hayward, CA USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
10.1016/j.jval.2015.03.1628
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND8
引用
收藏
页码：A279 / A279
页数：1
相关论文
共 46 条
  • [31] Efficacy of IPX066, modified-release levodopa-carbidopa (NUMIENT™) in patients with advanced Parkinson's disease: responder analyses
    Gupta, S.
    Khanna, S.
    Rustay, N.
    Rubens, R.
    Kell, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 527 - 527
  • [32] Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease
    Mao, Zhongping Lily
    Modi, Nishit B.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (08): : 974 - 982
  • [33] The effects of duration of exposure on adverse event reporting in Parkinson's disease patients treated with IPX066 extended-release carbidopa-levodopa capsules
    Kell, S.
    Hsu, A.
    O'Connell, M.
    Simuni, T.
    Gupta, S.
    MOVEMENT DISORDERS, 2013, 28 : S148 - S149
  • [34] Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations
    Morgan, John C.
    Dhall, Rohit
    Rubens, Robert
    Khanna, Sarita
    Gupta, Suneel
    PARKINSONS DISEASE, 2018, 2018
  • [35] Extended-release carbidopa- levodopa, IPX066: Dosing and efficacy with concomitant medication use in Parkinson's disease
    Gupta, S.
    Khanna, S.
    Kell, S.
    Rubens, R.
    MOVEMENT DISORDERS, 2016, 31 : S670 - S670
  • [36] PHARMACODYNAMICS OF IPX066, AN EXTENDED-RELEASE CAPSULE FORMULATION OF CARBIDOPA-LEVODOPA (CD-LD), IN PATIENTS WITH EARLY PARKINSON'S DISEASE: A DISEASE PROGRESSION MODEL
    Mao, Z.
    Hsu, A.
    Gupta, S.
    Modi, N. B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S81 - S81
  • [37] Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial
    Waters, Cheryl H.
    Nausieda, Paul
    Dzyak, Lyudmila
    Spiegel, Joerg
    Rudzinska, Monika
    Silver, Dee E.
    Tsurkalenko, Elena S.
    Kell, Sherron
    Hsu, Ann
    Khanna, Sarita
    Gupta, Suneel
    CNS DRUGS, 2015, 29 (04) : 341 - 350
  • [38] Comparison of IPX066, a Novel Carbidopa-Levodopa (CD-LD) Extended-Release Formulation, and CD-LD-Entacapone (CLE) in Advanced Parkinson's Disease (ASCEND-PD Trial)
    Stocchi, Fabrizio
    Dillmann, Ulrich
    Ellenbogen, Aaron
    Hsu, Ann
    Khanna, Sarita
    Rubens, Robert
    Liang, Grace
    Gupta, Suneel
    NEUROLOGY, 2012, 78
  • [39] Comparison of IPX066, a novel investigational carbidopa-levodopa (CD-LD) extended-release formulation, and CD-LD-entacapone (CLE) in advanced Parkinson's disease (ASCEND-PD trial)
    Stocchi, F.
    Dillmann, U.
    Mahler, A.
    Ellenbogen, A.
    Liang, G.
    Hsu, A.
    Khanna, S.
    Rubens, R.
    Gupta, S.
    MOVEMENT DISORDERS, 2012, 27 : S140 - S140
  • [40] Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules
    Modi, Nishit B.
    Mittur, Aravind
    Rubens, Robert
    Khanna, Sarita
    Gupta, Suneel
    CLINICAL NEUROPHARMACOLOGY, 2019, 42 (01) : 4 - 8
12345